Drug Approvals International – Page 104 – All about Drugs Live by Dr Anthony Melvin Crasto

Eluxadoline, エルクサドリン ,элуксадолин ,إيلوكسادولين ,艾沙多林 ,

Eluxadoline Molecular FormulaC32H35N5O5 Average mass569.651 Da 5-({[(2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid 864821-90-9 CAS JNJ-27018966 Molecular Formula: C32H35N5O5 Molecular Weight: 569.6508 Agents for Irritable Bowel Syndrome, mu-Opioid Agonists, delta-Opioid Antagonists Eluxadoline Trade Name: Viberzi® Research Code: JNJ-27018966, JNJ27018966, JNJ 27018966 Chemical Name: 5 – [[[(2S) -2-amino-3- [4- (aminocarbonyl) -2,6-dimethylphenyl ] -1- oxopropyl] [(1S) -1- (4-phenyl-1H-imidazol-2-yl) ethyl] amino] methyl] -2-methoxybenzoic acid MOA: mu opioid …

ROLAPITANT, ロラピタント

ROLAPITANT HYDROCHLORIDE Rolapitant HCl Rolapitant hydrochloride Sch 619734 SCH619734 UNII-57O5S1QSAQ (5S ,8S)-8-[[(1R)-1-[3 ,5- Bis(trifluoromethyl)phenyl] ethoxy] methyl]-8-phenyl-1,7- diazaspiro[4.5]decan-2-one hydrochloride monohydrate. CAS 914462-92-3 Empirical Formula: C25H26F6N2O2 · HCl · H2O, Molecular Weight: 555 USAN Name: Rolapitant hydrochloride, INN Name: rolapitantum or rolapitant CAS Number: 552292-08-7 (rolapitant free base); 914462-92-3 (rolapitant HCl monohydrdate). Rolapitant Molecular FormulaC25H26F6N2O2 Average mass500.477 Da (5S,8S)-8-({(1R)-1-[3,5-Bis(trifluorométhyl)phényl]éthoxy}méthyl)-8-phényl-1,7-diazaspiro[4.5]décan-2-one 1,7-Diazaspiro[4.5]decan-2-one, 8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-, (5S,8S)- 552292-08-7 [RN] 8882 NLE429IZUC …

Selexipag, セレキシパグ ,селексипаг , سيليكسيباق ,

Selexipag Molecular FormulaC26H32N4O4S Average mass496.622 Da Selexipag, Uptravi 475086-01-2 CAS (C26H32N4O4S, Mr = 496.6 g/mol) A prostacyclin receptor (PGI2) agonist used to treat pulmonary arterial hypertension (PAH). NIPPON SHINYAKU….INNOVATOR セレキシパグ UNII-5EXC0E384L селексипаг [Russian] [INN] سيليكسيباق [Amharic] [INN] 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methylsulfonyl)acetamide 475086-01-2 [RN] 5EXC0E384L 9231 Acetamide, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)- Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (MRE-269) (the …

VIXOTRIGINE, раксатригин , راكساتريجين , 维索曲静 ,

VIXOTRIGINE Molecular FormulaC18H19FN2O2 Average mass314.354 Da раксатригин , راكساتريجين , 维索曲静 , (5R)-5-{4-[(2-Fluorobenzyl)oxy]phényl}-L-prolinamide 10287 2-Pyrrolidinecarboxamide, 5-[4-[(2-fluorophenyl)methoxy]phenyl]-, (2S,5R)- 934240-30-9 [RN] QQS4J85K6Y Raxatrigine UNII:QQS4J85K6Y Vixotrigine (INN, USAN), formerly known as raxatrigine (INN, USAN), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker.[4]Following this, vixotrigine was redefined once again, as …

Omidenepag isopropyl, オミデネパグイソプロピル

Omidenepag isopropyl DE-117 Glycine, N-(6-((((4-(1H-pyrazol-1-yl)phenyl)methyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)-, 1-methylethyl ester [[6-[[[4-(Pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)amino]methyl]pyridin-2-yl]amino]acetic acid isopropyl ester C26H28N6O4S, 520.6033, CAS: 1187451-19-9 APPROVED 2018/9/21 PMDA, JAPAN 2018, Eybelis Antiglaucoma, Prostaglandin E2 receptor agonist, Treatment of Open-Angle Glaucoma and Ocular Hypertension Originator Ube Industries Developer Santen Pharmaceutical Class Eye disorder therapies; Pyrazoles; Pyridines; Small molecules; Sulfonamides Mechanism of Action Prostaglandin E EP2 receptor agonists Registered Glaucoma; Ocular hypertension 27 Sep 2018 Santen initiates enrolment …

FDA approves first treatment Gamifant (emapalumab) specifically for patients with rare and life-threatening type of immune disease

FDA approves first treatment Gamifant (emapalumab) specifically for patients with rare and life-threatening type of immune disease The U.S. Food and Drug Administration today approved Gamifant (emapalumab) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance with conventional HLH …

Lumateperone

Lumateperone Molecular FormulaC24H28FN3O Average mass393.497 Da 4-((6bR,10aS)-3-Methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 1-Butanone, 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)- 1-(4-fluorophenyl)-4-{4-methyl-1,4,12-triazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-5,7,9(16)-trien-12-yl}butan-1-one 313368-91-1 [RN] 70BSQ12069, Lumateperone, PHASE 3, ITI-007 4- methylbenzenesulfonate. SALT Molecular Formula: C31H36FN3O4S Molecular Weight: 565.704 g/mol (6bR,10aS)-8-[4-(4-Fluorophenyl)-4-oxobutyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3‘,4’:4,5]pyrrolo[1,2,3-de]quinoxalin-8-ium 4-methylbenzenesulfonate 1187020-80-9 [RN] 1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-, 4-methylbenzenesulfonate (1:1) ITI-007 tosylate JIE88N006O Lumateperone tosylate [USAN] UNII:JIE88N006O ITI 007 Originator Bristol-Myers Squibb Develope rIntra-Cellular Therapies Class Antidepressants; Antipsychotics; Pyrroles; Quinoxalines; Sleep disorder therapies Mechanism of Action Dopamine receptor …

Nemorexant

Nemorexant ACT-541468, UNII LMQ24G57E9 [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone 1505484-82-1 [RN] LMQ24G57E9 Methanone, [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]- Originator Actelion Pharmaceuticals Developer Idorsia Pharmaceuticals Class Sleep disorder therapies Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists Phase III Insomnia 19 Oct 2018 Idorsia Pharmaceuticals plans a phase I trial for Liver disorders (Hepatic impairment) in November 2018 (PO) (NCT03713242) 09 Oct 2018 Idorsia …

Eflornithine, эфлорнитин , إيفلورنيثين , 依氟鸟氨酸 , エフロルニチン

Eflornithine DFMO, RMI-71782ATC:P01CX03, BRN 2250529 / HSDB 7923 / MDL 71782 / RFI 7178 / RMI 71782 Ornithine, 2-(difluoromethyl)- UNII:ZQN1G5V6SR ZQN1G5V6SR эфлорнитин [Russian] [INN] إيفلورنيثين [Arabic] [INN] 依氟鸟氨酸 [Chinese] [INN] エフロルニチン 5551 67037-37-0 [RN] 70052-12-9 CAS a-Difluoromethylornithine (RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid Use:hirsutism treatment inhibitor of ornithine decarboxylase Chemical name:2-(difluoromethyl)-dl-ornithine Formula:C6H12F2N2O2, MW:182.17 g/mol CAS-RN:67037-37-0 LD50:>3000 mg/kg (M, i.p.); >5000 mg/kg (M, p.o.); 1364 μg/kg (R, intracerebral) Eflornithine, also known as α-difluoromethylornithine (DFMO), is an Active …

Pirlindole

Pirlindole Molecular FormulaC15H18N2 Average mass226.317 Da 1H-Pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino[3,2,1-jk]carbazole 4615 60762-57-4 [RN] FREE FORM, 16154-78-2 (hydrochloride) 12-methyl-1,4-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-9(16),10,12,14-tetraene 8-Methyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]carbazole UNII:V39YPH45FZ V39YPH45FZ INNOVATOR Russian Academy of Medical Sciences For the treatment of major depression. Pirlindole is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is currently used in Russia as an antidepressant. It is structurally and pharmacologically related …